JSKN 001
Alternative Names: JSKN-001Latest Information Update: 04 Feb 2021
At a glance
- Originator Alphamab Oncology
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 25 Jan 2021 Preclinical trials in Solid tumours in China (unspecified route) before January 2021 (Alphamab Oncology pipeline, January 2021)
- 22 Jan 2021 JSKN 001 is available for licensing as of 25 Jan 2021. http://www.alphamabonc.com/en/company/partnering.html (Alphamab Oncology Website, January 2021)